FrancophonIA/ELRC3.0 huggingface dataset:
English: In this study, 98.2% of the patients received other antihyperglycaemic treatments (75.3% on insulin and 31.2% on oral antihyperglycaemics; some received both).
Danish: I denne undersøgelse fik 98,2 % af patienterne anden antihyperglykæmisk behandling (75,3 % fik insulin og 31,2 % fik orale antihyperglykæmiske lægemidler; nogle fik begge dele).
English: decision must be made whether to discontinue breast-feeding or to discontinue therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy to the woman.
Danish: Det skal besluttes, om amning skal ophøre eller behandling med saxagliptin seponeres, idet der tages højde for fordelene ved amning for barnet i forhold til de terapeutiske fordele for moderen.
English: The inhibition of plasma DPP4 activity by saxagliptin for at least 24 hours after oral administration of saxagliptin is due to high potency, high affinity, and extended binding to the active site.
Danish: Saxagliptins hæmning af plasma DPP4- aktivitet i mindst 24 timer efter oral administration skyldes høj potens, høj affinitet og forlænget binding til det aktive bindingssted.
English: Therefore, a lower dose of sulphonylurea or insulin may be required to reduce the risk of hypoglycaemia when used in combination with Onglyza.
Danish: Derfor kan en lavere dosis af sulfonylurinstof eller insulin være nødvendig for at reducere risikoen for hypoglykæmi, når det anvendes i kombination med Onglyza.
English: In the confirmatory full analysis set, mean reductions were -0.4% and -0.6% respectively for saxagliptin and sitagliptin, with median reductions of -0.5% for both groups.
Danish: I det bekræftende fulde analysesæt var de gennemsnitlige reduktioner hhv. -0,4 % og -0,6 % for saxagliptin og sitagliptin med gennemsnitlige reduktioner på -0,5 % for begge grupper.
English: Onglyza should not be used in place of insulin;
Danish: Onglyza må ikke bruges i stedet for insulin.
English: A lower proportion of patients in the saxagliptin group (1.1%) compared to the glimepiride group (15.3%) experienced a confirmed or severe hypoglycaemic event.
Danish: En lavere andel af patienter i saxagliptingruppen (1,1 %) sammenlignet med glimepiridgruppen (15,3 %) havde en bekræftet eller alvorlig hypoglykæmisk episode.
English: The tablets contain lactose (milk sugar).
Danish: Tabletterne indeholder lactose (mælkesukker).
English: Swallow the tablet whole with some water.
Danish: Synk tabletten hel og drik samtidig et glas vand.
English: The European Medicines Agency has deferred the obligation to submit the results of studies with Onglyza in one or more subsets of the paediatric population in the treatment of type 2 diabetes mellitus (see section 4.2 for information on paediatric use).
Danish: Det Europiske Lægemiddelagentur har udsat forpligtelsen til at fremlægge resultaterne af studier med Onglyza i en eller flere undergrupper af den pædiatriske population med type 2-diabetes mellitus (se pkt.
English: Saxagliptin improves glycaemic control by reducing fasting and postprandial glucose concentrations in patients with type 2 diabetes.
Danish: Saxagliptin forbedrer den glykæmiske kontrol ved at reducere faste- og postprandiale glucosekoncentrationer hos patienter med type 2-diabetes.
English: In in vitro studies, saxagliptin and its major metabolite neither inhibited CYP1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, or 3A4, nor induced CYP1A2, 2B6, 2C9, or 3A4.
Danish: I in vitro forsøg hæmmede saxagliptin og dets hovedmetabolit hverken CYP1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1 eller 3A4 og saxagliptin eller dets hovedmetabolit inducerede ikke CYP1A2, 2B6, 2C9 eller 3A4.
English: The SAVOR trial included 8240 patients treated with Onglyza 5 mg or 2.5 mg once daily and 8173 patients on placebo.
Danish: SAVOR-studiet omfattede 8.240 patienter, som blev behandlet med Onglyza 5 mg eller 2,5 mg én gang dagligt, og 8.173 patienter på placebo.
English: GENERATION was a 52-week glycaemic control study in 720 elderly patients, the mean age was 72.6 years; 433 subjects (60.1%) were < 75 years of age, and 287 subjects (39.9%) were ≥ 75 years of age.
Danish: GENERATION var et 52 ugers studie af glykæmisk kontrol hos 720 ældre patienter, hvor den gennemsnitlige alder var 72,6 år; 433 forsøgspersoner (60,1 %) var < 75 år, og 287 forsøgspersoner (39,9 %) var ≥ 75 år.
English: Saxagliptin also resulted in a significantly lower proportion of patients with hypoglycaemia, 3% (19 events in 13 subjects) vs. 36.3% (750 events in 156 patients) for glipizide.
Danish: Saxagliptin medførte også en signifikant lavere andel af patienter med hypoglykæmi, 3 % (19 hændelser i 13 forsøgspersoner) vs. 36,3 % (750 hændelser i 156 patienter) for glipizid.
English: Onglyza is used alone or together with insulin or other anti-diabetic medicines.
Danish: Onglyza bruges alene eller sammen med insulin eller anden antidiabetisk medicin.
English: The primary safety (noninferiority) and efficacy (superiority) endpoint was a composite endpoint consisting of the time-to-first occurrence of any of the following major adverse CV events (MACE): CV death, nonfatal myocardial infarction, or nonfatal ischaemic stroke.
Danish: De primære endepunkter for sikkerhed (non inferioritet) og virkning (superioritet) var et sammensat endepunkt bestående af tiden til første forekomst af en af følgende svære kardiovaskulære bivirkninger (MACE): kardiovaskulær død, ikke dødeligt myokardieinfarkt eller ikke dødelig iskæmisk apopleksi.
English: The rise in insulin from pancreatic beta-cells and the decrease in glucagon from pancreatic alpha-cells were associated with lower fasting glucose concentrations and reduced glucose excursion following an oral glucose load or a meal.
Danish: Stigningen i insulin fra beta-celler i pankreas og reduktionen af glukagon fra alfa-celler i pankreas var associeret med lavere glucosekoncentrationer under faste og nedsat glucoseudsving efter en oral glucosebelastning eller et måltid.
English: • Study CV181039: initial combination with metformin Overall population (n=306) Baseline HbA1c ≥ 10% stratum (n=107)
Danish: • Studie CV181039: initial kombination med metformin Hele populationen (n=306) Baseline HbA1c ≥10 % stratum (n=107)
English: If you take more Onglyza than you should If you take more tablets than you should, talk to a doctor straight away.
Danish: Hvis du har taget for meget Onglyza Hvis du har taget for mange tabletter, skal du straks tale med lægen.
English: The average renal clearance of saxagliptin (~230 ml/min) was greater than the average estimated glomerular filtration rate (~120 ml/min), suggesting some active renal excretion.
Danish: Den gennemsnitlige renale clearance af saxagliptin (230 ml/min) var større end den gennemsnitlige estimerede glomerulære filtrationshastighed (120 ml/min), hvilket tyder på en vis aktiv nyreudskillelse.
English: Because the dose should be limited to 2.5 mg based upon renal function, assessment of renal function is recommended prior to initiation of treatment, and, in keeping with routine care, renal assessment should be done periodically thereafter (see sections 4.4 and 5.2).
Danish: Da dosen bør begrænses til 2,5 mg på baggrund af en vurdering af nyrefunktionen, anbefales det, at der udføres en vurdering af nyrefunktionen inden påbegyndelse af behandlingen og, i overensstemmelse med den rutinemæssige behandling, periodevist derefter (se pkt.
English: • Printing ink: shellac; indigo carmine aluminium lake (E132).
Danish: • Tryk: Shellac, indigo carmine aluminium lake (E132).
English: A total of 22% of the administered radioactivity was recovered in faeces representing the fraction of the saxagliptin dose excreted in bile and/or unabsorbed medicinal product from the gastrointestinal tract.
Danish: I alt 22 % af den administrerede radioaktivitet blev genfunden i fæces og udgjorde den fraktion af saxagliptindosis som udskilles i galden og/eller uabsorberet lægemiddel fra den gastrointestinale tragt.
English: Metabolism and nutrition disorders Hypoglycaemia
Danish: Metabolisme og ernæring Hypoglykæmi
English: Do not use this medicine after the expiry date which is stated on the blister and the carton after EXP.
Danish: Brug ikke lægemidlet efter den udløbsdato, der står på blister og pakning efter EXP. Udløbsdatoen er den sidste dag i den nævnte måned.
English: Reductions in HbA1c from baseline to Week 24 were observed in all evaluated subgroups defined by baseline HbA1c, with greater reductions observed in patients with a baseline HbA1c ≥ 10% (see Table 2).
Danish: Reduktioner i HbA1c fra baseline frem til uge 24 blev observeret hos alle evaluerede undergrupper, defineret ud fra baseline HbA1c, med større reduktioner set hos patienter med en baseline HbA1c ≥ 10 % (se tabel 3).
English: Acute Pancreatitis
Danish: Akut pankreatitis
English: In addition, patients should be alerted to the risk of hypoglycaemia when Onglyza is used in combination with other antidiabetic medicinal products known to cause hypoglycaemia (e.g. insulin, sulphonylureas).
Danish: Derudover skal patienterne advares om risikoen for hypoglykæmi, når Onglyza anvendes i kombination med andre antidiabetika, der er kendt for at medføre hypoglykæmi (f.eks. insulin, sulfonylurinstoffer).
English: In both studies, once-daily treatment with saxagliptin provided significant improvements in HbA1c (see Table 2).
Danish: I begge studier medførte behandling med saxagliptin en gang daglig signifikante forbedringer i HbA1c (se tabel 3).
English: Studies in animals have shown reproductive toxicity at high doses (see section 5.3).
Danish: Dyrestudier har påvist reproduktionstoksicitet ved høje doser (se pkt.
English: 2 from baseline HbA1c (%) at Week 24
Danish: 2 fra baseline HbA1c(%) i uge 24
English: Adverse reactions were identified through postmarketing surveillance.
Danish: Bivirkninger, der er identificeret i forbindelse med overvågningen efter markedsføring.
English: The incidence of confirmed hypoglycaemia was uncommon for Onglyza 5 mg (0.8%) and placebo (0.7%).
Danish: Forekomsten af bekræftet hypoglykæmi var ikke almindelig med Onglyza 5 mg (0,8 %) og placebo (0,7 %).
English: Proportion of patients achieving HbA1c < 7%
Danish: Andel af patienter, der opnåede HbA1c <7 %
English: The safety and efficacy of saxagliptin as triple oral therapy in combination with metformin and a thiazolidinedione have not been established.
Danish: Saxagliptins sikkerhed og effekt som oral tripelbehandling med metformin og thiazolidindion er ikke fastslået.
English: After 18 weeks, saxagliptin was non-inferior to sitagliptin in mean reduction from baseline in HbA1c in both the per-protocol and the full analysis sets.
Danish: Efter 18 uger var saxagliptin non-inferior i forhold til sitagliptin, hvad angik gennemsnitlig reduktion fra baseline i HbA1c ved per-protokol-analysen og fuld analyse.
English: Food had relatively modest effects on the pharmacokinetics of saxagliptin in healthy subjects.
Danish: Føde har relativ beskeden effekt på saxagliptins farmakokinetik hos raske forsøgspersoner.
English: Caution is warranted if Onglyza is used in patients who have known risk factors for hospitalisation for heart failure, such as a history of heart failure or moderate to severe renal impairment.
Danish: Forsigtighed tilrådes, hvis Onglyza anvendes til patienter, som har kendte risikofaktorer for hospitalsindlæggelse for hjertesvigt, såsom hjertesvigt eller moderat til svært nedsat nyrefunktion, i anamnesen.
English: No appreciable accumulation of either saxagliptin or its major metabolite was observed with repeated once-daily dosing at any dose level.
Danish: Der er ikke observeret nogen betydelig akkumulering af hverken saxagliptin eller hovedmetabolitten ved gentagne daglige engangsdoseringer på noget dosisniveau.
English: Another secondary endpoint, all-cause mortality, occurred at a rate of 5.1% in the saxagliptin group and 4.6% in the placebo group (see Table 4).
Danish: Et andet sekundært endepunkt, total mortalitet, forekom i en frekvens på 5,1 % i saxagliptingruppen og 4,6 % i placebogruppen (se tabel 4).
English: It is unknown whether saxagliptin is excreted in human breast milk.
Danish: Det er ukendt, om saxagliptin udskilles i human mælk.
English: The safety and efficacy of Onglyza in children aged birth to < 18 years have not yet been established.
Danish: Onglyzas sikkerhed og virkning hos børn i alderen 0 måneder til < 18 år er endnu ikke klarlagt: Der foreligger ingen data.
English: Saxagliptin was rapidly absorbed after oral administration in the fasted state, with maximum plasma concentrations (Cmax) of saxagliptin and its major metabolite attained within 2 and 4 hours (Tmax), respectively.
Danish: Saxagliptin absorberedes hurtigt efter oral administration i fastende tilstand og maksimale plasmakoncentrationer (Cmax) af saxagliptin og hovedmetabolitten opnåedes inden for henholdsvis 2 og 4 timer (Tmax).
English: Onglyza contains less than 1 mmol sodium (23 mg) per dose, i.e. is essentially ‘sodium-free'.
Danish: Onglyza indeholder mindre end 1 mmol natrium (23 mg) per dosis, dvs. den er i det væsentlige ”natriumfri”.
English: Some patients have had the following additional side effects while taking Onglyza alone: • Common: dizziness, diarrhoea and stomach ache.
Danish: Nogle patienter har desuden haft følgende bivirkning, når de har taget Onglyza alene: • Almindelig: Svimmelhed, diarré og mavepine.
English: The overall incidence of adverse events in patients treated with Onglyza in this trial was similar to placebo (72.5% versus 72.2%, respectively).
Danish: Den samlede bivirkningsfrekvens hos patienter, der blev behandlet med Onglyza i dette studie var sammenlignelig med den for placebo (henholdsvis 72,5 % versus 72,2 %).
English: • if you have reduced kidney function, your doctor will decide if you need to take a lower dose of Onglyza.
Danish: • hvis du har nedsat nyrefunktion, vil din læge bestemme, om du skal tage en lavere dosis Onglyza.
English: The incidence of confirmed hypoglycaemic events was somewhat higher in the saxagliptin group (9.4%) versus placebo group (4.7%) although the number of subjects with any hypoglycaemic event did not differ between the treatment groups.
Danish: Forekomsten af bekræftede hypoglykæmiske hændelser var noget højere i saxagliptin-gruppen (9,4 %) i forhold til placebogruppen (4,7 %), dog afveg antallet af forsøgspersoner med enhver form for hypoglykæmisk hændelse ikke mellem behandlingsgrupperne.
English: Each tablet contains 99 mg lactose (as monohydrate).
Danish: Hver tablet indeholder 99 mg lactose (som monohydrat).
English: This is a medicine used to lower blood pressure.
Danish: Dette er blodtrykssænkende medicin.
English: If a serious hypersensitivity reaction to saxagliptin is suspected, Onglyza should be discontinued, assess for other potential causes for the event, and institute alternative treatment for diabetes (see section 4.8).
Danish: Ved mistanke om en alvorlig overfølsomhedsreaktion over for saxagliptin bør Onglyza seponeres, evaluer for andre mulige årsager til hændelsen og skift til anden antidiabetisk behandling (se pkt.
English: What Onglyza contains - The active substance is saxagliptin.
Danish: Onglyza indeholder: - Aktivt stof: Saxagliptin.
English: This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say it is essentially ‘sodium-free'.
Danish: Denne medicin indeholder mindre end 1 mmol natrium (23 mg) per dosis, dvs. den er i det væsentlige natriumfri.
English: The pharmacokinetics of saxagliptin and its major metabolite were similar in healthy subjects and in patients with type 2 diabetes.
Danish: Farmakokinetikken for saxagliptin og hovedmetabolitten var sammenlignelige hos raske personer og patienter med type 2-diabetes.
English: Least squares mean adjusted for baseline value.
Danish: Mindste kvadraters metode justeret for baseline-værdier.
English: After an oral glucose load, this DPP4 inhibition resulted in a 2- to 3-fold increase in circulating levels of active incretin hormones, including glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), decreased glucagon concentrations and increased glucose-dependent beta-cell responsiveness, which resulted in higher insulin and C-peptide concentrations.
Danish: Efter en oral glucose-belastning resulterede denne DPP4-hæmning i en 2 til 3-fold stigning i de cirkulerende niveauer af aktive inkretinhormoner, inklusive glukagonlignende peptid-1 (GLP-1) og glucoseafhængigt insulinotropt polypeptid (GIP), et fald i glukagonkoncentrationer og øgning af den glucoseafhængige beta-cellereaktionsevne, hvilket resulterede i højere koncentrationer af insulin og C-peptid .
English: The time for saxagliptin to reach Cmax (Tmax) was increased by approximately 0.5 hours with food compared with the fasted state.
Danish: Tiden for opnåelse af Cmax (Tmax) for saxagliptin blev øget med omtrent 0,5 time ved fødeindtagelse sammenlignet med fastende tilstand.
English: Some patients have had a small reduction in the number of one type of white blood cells (lymphocytes) shown in a blood test when Onglyza was used alone or in combination.
Danish: Nogle patienter har haft en lille reduktion i antallet af en bestemt type hvide blodlegemer (lymfocytter) ved anvendelse af Onglyza alene eller sammen med andre lægemidler.
English: Similar HbA1c reductions versus placebo were achieved for patients receiving saxagliptin 5 mg add-on to insulin regardless of metformin use (−0.4% for both subgroups).
Danish: Tilsvarende reduktion i HbA1c versus placebo blev opnået hos patienter, der fik saxagliptin 5 mg som tillæg til insulin uanset brug af metformin (-0,4 % for begge subgrupper).
English: Patients treated with saxagliptin exhibited a significant decrease from baseline in body weight compared to a weight gain in patients administered glipizide (-1.1 vs. +1.1 kg).
Danish: Hos de patienter, der blev behandlet med saxagliptin, sås en signifikant reduktion af kropsvægt fra baseline sammenlignet med en vægtøgning hos patienter, der fik glipizid (-1,1 vs. +1,1 kg).
English: Improvements in HbA1c following treatment with saxagliptin 2.5 mg were sustained up to Week 52, however, the number of patients who completed 52 weeks without modification of other antihyperglycaemic treatment was low (26 subjects in the saxagliptin group versus 34 subjects in the placebo group).
Danish: Forbedringerne i HbA1c efter behandlingen med saxagliptin 2,5 mg var vedvarende frem til uge 52, men antallet af patienter, som gennemførte 52 ugers behandling uden justeringer af anden antihyperglykæmisk behandling, var lavt (26 forsøgspersoner i saxagliptin-gruppen over for 34 forsøgspersoner i placebogruppen).
English: The incidence of diarrhoea was 4.1% (36/882) in the saxagliptin 5 mg group and 6.1% (49/799) in the placebo group.
Danish: Incidensen af diarré var 4,1 % (36/882) i den gruppe, der fik saxagliptin 5 mg, og 6,1 % (49/799) i den gruppe, der fik placebo.
English: Mean baseline HbA1c
Danish: Gennemsnitlige baseline HbA1c
English: In cynomolgus monkeys saxagliptin produced reversible skin lesions (scabs, ulcerations and necrosis) in extremities (tail, digits, scrotum and/or nose) at doses ≥ 3 mg/kg/day.
Danish: Hos cynomolgusaber medførte saxagliptin reversible hudlæsioner (sårskorper, sårdannelse og nekrose) i ekstremiteterne (hale, tæer/fingre, skrotum og/eller næse) ved doser ≥3 mg/kg/dag.
English: Onglyza must not be used in patients who have had any serious hypersensitivity reaction to a dipeptidyl peptidase-4 (DPP4) inhibitor (see section 4.3).
Danish: Onglyza må ikke anvendes til patienter, som har haft alvorlige overfølsomhedsreaktioner over for en dipeptidylpeptidase-4- (DPP-4-) hæmmer (se pkt.
English: The mean plasma terminal half-life (t1/2) values for saxagliptin and its major metabolite are 2.5 hours and 3.1 hours respectively, and the mean t1/2 value for plasma DPP4 inhibition was 26.9 hours.
Danish: De gennemsnitlige terminale plasmahalveringstider (t1/2) for saxagliptin og hovedmetabolitten er 2,5 timer henholdsvis 3,1 timer og den gennemsnitlige t1/2 for inhibering af plasma-DPP4 var 26,9 timer.
English: • Uncommon: tiredness, abnormal lipid (fatty acids) levels (dyslipidaemia, hypertriglyceridaemia).
Danish: • Ikke almindelig: Træthed, unormale lipid (fedtsyre)-niveauer (dyslipidæmi, hypertriglyceridæmi).
English: As initial combination with metformin, myalgia is reported as uncommon.
Danish: Ved initial kombination med metformin er myalgi indrapporteret med hyppigheden ikke almindelig.
English: Method of administration The tablets can be taken with or without a meal at any time of the day.
Danish: Tabletterne kan tages sammen med eller uden et måltid uafhængigt af tidspunktet på dagen.
English: MONOTHERAPY STUDIES
Danish: MONOTERAPI STUDIER
English: In studies conducted in healthy subjects, neither the pharmacokinetics of saxagliptin nor its major metabolite, were meaningfully altered by metformin, glibenclamide, pioglitazone, digoxin, simvastatin, omeprazole, antacids or famotidine.
Danish: I kliniske forsøg udført på raske forsøgspersoner blev hverken farmakokinetikken af saxagliptin eller dets hovedmetabolit betydeligt ændret af metformin, glibenclamid, pioglitazon, digoxin, simvastatin, omeprazol, antacida eller famotidin.
English: The study population included those ≥65 years (n=8561) and ≥ 75 years (n=2330), with normal or mild renal impairment (n=13,916) as well as moderate (n=2240) or severe (n=336) renal impairment.
Danish: Studiepopulationen omfattede patienter ≥65 år (n=8.561) og ≥75 år (n=2.330) med normal eller let nedsat nyrefunktion (n=13.916), moderat (n=2.240) eller svært (n=336) nedsat nyrefunktion.
English: The study included patients with renal impairment classified on the basis of creatinine clearance as mild (approximately GFR ≥ 45 to < 90 mL/min), moderate (approximately GFR ≥ 30 to < 45 mL/min), or severe (approximately GFR < 30 mL/min), as well as patients with ESRD on haemodialysis.
Danish: Undersøgelsen omfattede patienter med nedsat nyrefunktion, der blev klassificeret på baggrund af kreatinin-clearance som let (ca. GFR ≥ 45 til <90 ml/min), moderat (ca. GFR ≥ 30 til <45 ml/min ) eller svært nedsat (ca. GFR < 30 ml/min ) samt patienter med ESRD i hæmodialyse.
English: Saxagliptin with a thiazolidinedione
Danish: Saxagliptin med et thiazolidinedion
English: Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu.
Danish: Yderligere information om Onglyza findes på Det Europæiske Lægemiddelagenturs hjemmeside http://www.ema.europa.eu.
English: Table 2 Key efficacy results of Onglyza 5 mg per day in placebo-controlled monotherapy trials and in add-on combination therapy trials
Danish: Nøgleresultater af effekten af Onglyza 5 mg dagligt i placebo-kontrollerede monoterapi-forsøg og i forsøg med tillægs-kombinationsbehandling
English: Dipeptidyl peptidase 4 (DPP4) inhibitors, ATC code: A10BH03
Danish: Farmakoterapeutisk klassifikation: Antidiabetika: Dipeptidylpeptidase-4- (DPP4-) hæmmere, ATC-kode: A10BH03
English: The dose should be reduced to 2.5 mg once daily in patients with moderate renal impairment that have GFR < 45 mL/min and in patients with severe renal impairment.
Danish: Dosis skal reduceres til 2,5 mg én gang dagligt hos patienter med moderat nyrefunktion, som har GFR < 45 ml/min og hos patienter med svært nedsat nyrefunktion.
English: The decreases in lymphocyte count were not associated with clinically relevant adverse reactions.
Danish: Faldet i lymfocyttal var ikke associeret med klinisk relevante bivirkninger.
English: The Cmax and AUC values of saxagliptin and its major metabolite increased proportionally with the increment in the saxagliptin dose, and this dose-proportionality was observed in doses up to 400 mg.
Danish: Cmax og AUC værdier for saxagliptin og hovedmetabolitten øgedes proportionalt med øgningerne i saxagliptin-dosis, og denne dosis-proportionalitet blev observeret i doser på op til 400 mg.
English: No dose adjustment is recommended for patients with mild renal impairment or in patients with moderate renal impairment that have GFR ≥ 45 mL/min.
Danish: Det er ingen anbefalinger om dosisjusteringer hos patienter med let nedsat nyrefunktion eller hos patienter med moderat nedsat nyrefunktion, som har GFR ≥ 45 ml/min..